MX388142B - Anticuerpos tau humanizados en enfermedad de alzheimer. - Google Patents

Anticuerpos tau humanizados en enfermedad de alzheimer.

Info

Publication number
MX388142B
MX388142B MX2017006663A MX2017006663A MX388142B MX 388142 B MX388142 B MX 388142B MX 2017006663 A MX2017006663 A MX 2017006663A MX 2017006663 A MX2017006663 A MX 2017006663A MX 388142 B MX388142 B MX 388142B
Authority
MX
Mexico
Prior art keywords
disease
alzheimer
tau antibodies
humanized tau
humanized
Prior art date
Application number
MX2017006663A
Other languages
English (en)
Other versions
MX2017006663A (es
Inventor
Branislav Kovacech
Eva Kontsekova
Michal Novak
Rostislav Skrabana
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Publication of MX2017006663A publication Critical patent/MX2017006663A/es
Publication of MX388142B publication Critical patent/MX388142B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

La presente invención está en los campos de bioquímica, biología molecular, y diagnosis, prevención y tratamiento de enfermedad de Alzheimer. En la presente solicitud se proveen anticuerpos humanizados contra tau de humano que son capaces de discriminar entre tau normal (sana) y tau patológica (asociada a enfermedad).
MX2017006663A 2014-11-19 2015-11-18 Anticuerpos tau humanizados en enfermedad de alzheimer. MX388142B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462081809P 2014-11-19 2014-11-19
PCT/IB2015/002610 WO2016079597A1 (en) 2014-11-19 2015-11-18 Humanized tau antibodies in alzheimer's disease

Publications (2)

Publication Number Publication Date
MX2017006663A MX2017006663A (es) 2017-08-21
MX388142B true MX388142B (es) 2025-03-19

Family

ID=55411706

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017006663A MX388142B (es) 2014-11-19 2015-11-18 Anticuerpos tau humanizados en enfermedad de alzheimer.
MX2021014367A MX2021014367A (es) 2014-11-19 2017-05-19 Anticuerpos tau humanizados en enfermedad de alzheimer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014367A MX2021014367A (es) 2014-11-19 2017-05-19 Anticuerpos tau humanizados en enfermedad de alzheimer.

Country Status (24)

Country Link
US (3) US10160799B2 (es)
EP (2) EP3221349B1 (es)
JP (3) JP6830061B2 (es)
KR (1) KR20170126855A (es)
CN (1) CN107428820B (es)
AU (2) AU2015348012B2 (es)
BR (1) BR112017010498A2 (es)
CA (1) CA2966964A1 (es)
CY (1) CY1123746T1 (es)
DK (1) DK3221349T3 (es)
ES (1) ES2848376T3 (es)
HR (1) HRP20210124T1 (es)
HU (1) HUE053239T2 (es)
IL (2) IL251921B (es)
LT (1) LT3221349T (es)
MX (2) MX388142B (es)
PL (1) PL3221349T3 (es)
PT (1) PT3221349T (es)
RS (1) RS61431B1 (es)
RU (2) RU2730668C2 (es)
SG (1) SG11201703237VA (es)
SI (1) SI3221349T1 (es)
SM (1) SMT202100055T1 (es)
WO (1) WO2016079597A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
CN112553229A (zh) 2014-11-05 2021-03-26 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
ES2848376T3 (es) * 2014-11-19 2021-08-09 Axon Neuroscience Se Anticuerpos de tau humanizados en la enfermedad de Alzheimer
SG11201808434WA (en) * 2016-05-02 2018-10-30 Prothena Biosciences Ltd Antibodies recognizing tau
DK3452507T3 (da) 2016-05-02 2022-11-14 Prothena Biosciences Ltd Tau-immunoterapi
CU24538B1 (es) 2016-05-02 2021-08-06 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7
JP2020508054A (ja) * 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 抗タウ抗体及びその使用方法
US11028157B2 (en) * 2017-03-28 2021-06-08 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
BR112019022906A2 (pt) 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
WO2019048017A1 (en) * 2017-09-07 2019-03-14 Danmarks Tekniske Universitet METHODS FOR REMOVING NOX FROM A GAS STREAM CONTAINING MORE THAN ONE GAS COMPOUND
UA129617C2 (uk) 2017-10-16 2025-06-18 Еісаі Р Енд Д Менеджмент Ко., Лтд. Антитіло до тау та його застосування
JP7268039B2 (ja) 2018-02-01 2023-05-02 エヌケーマックス カンパニー リミテッド がん治療のためのナチュラルキラー細胞および組成物の製造方法
US12398201B2 (en) 2018-02-19 2025-08-26 New York University Tau single domain antibodies
RU2020135052A (ru) 2018-03-28 2022-04-29 Аксон Ньюросайенс Се Способы выявления и лечения болезни альцгеймера на основе антител
CN112166117A (zh) * 2018-05-03 2021-01-01 华盛顿大学 基于位点特异性tau磷酸化的诊断和治疗方法
AU2019268330A1 (en) 2018-05-15 2020-11-26 Voyager Therapeutics, Inc. Compositions and methods for the treatment of Parkinson's disease
AU2018446059A1 (en) * 2018-10-17 2021-05-20 The University Of Queensland Methods and compositions for treating tauopathies
SG11202104549TA (en) * 2018-11-08 2021-05-28 Prothena Biosciences Ltd Antibodies recognizing tau
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
CA3131531A1 (en) * 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
TWI877179B (zh) * 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
CA3147548A1 (en) * 2019-08-13 2021-02-18 Randall Bateman Methods to detect mtbr tau isoforms and use thereof
CA3150156A1 (en) 2019-09-09 2021-03-18 Michal Novak Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
MX2022002880A (es) 2019-09-10 2022-03-25 Washington University St Louis Ensayo basado en sangre para diagnosticar y tratar fosforilacion de tau especifica con base en el sitio.
MX2022007156A (es) * 2019-12-12 2022-09-07 Alector Llc Metodos de uso de anticuerpos anti-cd33.
WO2021173962A1 (en) * 2020-02-28 2021-09-02 Genemo, Inc. Methods and materials for diagnosis and treatment of neuronal disorder
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
CA3192987A1 (en) * 2020-09-22 2022-03-31 Kathleen E. Clarence-Smith Pharmaceutical combination for the treatment of human hypocholinergic disorders
CN112625129B (zh) * 2020-11-26 2022-05-20 江苏荃信生物医药股份有限公司 一种抗人白介素23及包含其的试剂盒及其检测方法
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
JP2023163821A (ja) * 2022-04-28 2023-11-10 国立大学法人鳥取大学 進行性核上性麻痺の診断マーカー
KR20250044781A (ko) * 2022-08-10 2025-04-01 주식회사 엔케이맥스 확장된 자연 살해 세포를 이용한 알츠하이머병 치료 방법
KR20250069606A (ko) 2022-09-15 2025-05-19 보이저 테라퓨틱스, 인크. 타우 결합 화합물
CA3237624A1 (en) * 2023-07-28 2025-04-24 Genentech, Inc. NEW USES FOR OMALIZUMAB
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2026005695A1 (en) * 2024-06-25 2026-01-02 Islam Tohidul Detection of oligomeric tau and soluble tau aggregates

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HU196394B (en) 1986-06-27 1988-11-28 Richter Gedeon Vegyeszet Process for preparing 2-halogenated ergoline derivatives
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
AU3144193A (en) 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
AU677216B2 (en) 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CA2142190C (fr) 1995-02-14 1998-01-27 Marc Lessard Conduite d'exfiltration d'air use
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
CN1177616C (zh) 1997-04-09 2004-12-01 曼德塞特生物制药公司 特异于β-淀粉状蛋白末端的重组抗体,编码它们的DNA及其使用方法
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ATE326700T1 (de) 1999-09-09 2006-06-15 Max Planck Gesellschaft SCREENING NACH INHIBITOREN VON ßGEPAARTEN HELIKALEN FILAMENTENß
WO2001062801A2 (en) 2000-02-24 2001-08-30 Washington University Humanized antibodies that sequester amyloid beta peptide
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
AU2001286930A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
EP2147679B1 (en) 2001-07-25 2014-06-25 Raptor Pharmaceutical, Inc. Compositions for blood-brain barrier transport
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
AU2003253044B2 (en) 2002-07-12 2009-08-13 Axon Neuroscience Se Truncated tau proteins
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
US7220833B2 (en) 2002-12-03 2007-05-22 Thomas Nelson Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
NZ541282A (en) 2002-12-24 2009-02-28 Bellus Health International Ltd Therapeutic formulations for the treatment of beta-amyloid related diseases
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP2625198B1 (en) * 2010-10-07 2015-07-22 AC Immune S.A. Antibodies recognising phospho-tau
US8940272B2 (en) * 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
SG10201912964PA (en) 2011-09-19 2020-02-27 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
EP2834270B1 (en) * 2012-04-05 2019-10-30 AC Immune S.A. Humanized tau antibody
BR112015014751A8 (pt) * 2012-12-21 2018-01-16 Biogen Int Neuroscience Gmbh anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
ES2848376T3 (es) * 2014-11-19 2021-08-09 Axon Neuroscience Se Anticuerpos de tau humanizados en la enfermedad de Alzheimer

Also Published As

Publication number Publication date
CY1123746T1 (el) 2022-05-27
BR112017010498A2 (pt) 2017-12-26
RU2730668C2 (ru) 2020-08-24
IL251921B (en) 2021-07-29
HUE053239T2 (hu) 2021-06-28
CA2966964A1 (en) 2016-05-26
PL3221349T3 (pl) 2021-05-17
JP6830061B2 (ja) 2021-02-17
HRP20210124T1 (hr) 2021-03-19
IL284250A (en) 2021-07-29
ES2848376T3 (es) 2021-08-09
AU2020227007B2 (en) 2024-05-30
MX2017006663A (es) 2017-08-21
IL251921A0 (en) 2017-06-29
LT3221349T (lt) 2021-02-10
JP6864763B2 (ja) 2021-04-28
RU2017120688A (ru) 2018-12-19
US20180142007A1 (en) 2018-05-24
US10745469B2 (en) 2020-08-18
RU2017120688A3 (es) 2019-07-17
US20210009666A1 (en) 2021-01-14
HK1244495A1 (en) 2018-08-10
EP3221349A1 (en) 2017-09-27
AU2015348012A1 (en) 2017-05-18
JP2018502558A (ja) 2018-02-01
CN107428820A (zh) 2017-12-01
AU2020227007A1 (en) 2020-09-17
JP2020141669A (ja) 2020-09-10
CN107428820B (zh) 2022-03-22
US11319363B2 (en) 2022-05-03
WO2016079597A1 (en) 2016-05-26
JP2021119774A (ja) 2021-08-19
SMT202100055T1 (it) 2021-03-15
SI3221349T1 (sl) 2021-02-26
EP3221349B1 (en) 2020-11-04
RU2020126237A (ru) 2020-12-01
US10160799B2 (en) 2018-12-25
EP3786182A1 (en) 2021-03-03
MX2021014367A (es) 2022-01-06
SG11201703237VA (en) 2017-06-29
RS61431B1 (sr) 2021-03-31
KR20170126855A (ko) 2017-11-20
PT3221349T (pt) 2021-01-21
WO2016079597A8 (en) 2020-07-02
DK3221349T3 (da) 2021-01-04
AU2015348012B2 (en) 2020-07-02
US20190169276A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
MX388142B (es) Anticuerpos tau humanizados en enfermedad de alzheimer.
JOP20200192A1 (ar) أجسام مضادة لـ tigit
SA519410311B1 (ar) أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
EA201992546A1 (ru) Средства на основе антител к cd33
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
WO2017030823A3 (en) Anti-tigit antibodies
EA201990778A1 (ru) Анти-il-33 антитела и их применение
WO2014124334A3 (en) Transthyretin antibodies and uses thereof
IL262799A (en) Synaptic protein biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders
MX392779B (es) Anticuerpos anti-cd27
PH12018500578A1 (en) Methods of treating inflammatory diseases
MX2018014028A (es) Inmunomoduladores de produccion de imagenes de tomografia por emision de positrones (pet).
WO2014197816A8 (en) Stimulus responsive nanocomplexes and methods of use thereof
WO2015117088A3 (en) Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
EA201890347A1 (ru) Антитела и исследования для обнаружения cd37
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
PH12019500434A1 (en) Anti-gm-csf antibodies and uses thereof
EP3294313A4 (en) METHODS RELATING TO THE PREVENTION AND TREATMENT OF DRUG RESISTANCE
LT3413870T (lt) Igmesinas, skirtas panaudoti alzheimerio ligos gydymui
WO2014053110A3 (de) Peptide zur behandlung und frühdiagnose von morbus alzheimer und anderer tauopathien
WO2016123329A3 (en) Gene expression markers and treatment of multiple sclerosis
CY1119674T1 (el) Θεραπεια και προληψη της νοσου αλτσχαϊμερ (ad)
EA201990493A1 (ru) Антитела к гм-ксф и их применения
EP3358012A4 (en) PREVENTION, DIAGNOSIS AND TREATMENT OF CANCER WITH GPR160 OVEREXPRESSION
WO2015113041A3 (en) Compositions and methods for treating autoimmune and inflammatory diseases